Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug3058 | Pravastatin Wiki | 1.00 |
| drug1533 | Filgotinib Wiki | 1.00 |
| drug3136 | Psychoeducation and Safety Wiki | 1.00 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D001172 | Arthritis, Rheumatoid NIH | 0.27 |
| D001168 | Arthritis NIH | 0.23 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| HP:0001370 | Rheumatoid arthritis HPO | 0.27 |
| HP:0001369 | Arthritis HPO | 0.23 |
Navigate: Correlations HPO
There is one clinical trial.
This cluster-randomized controlled trial (c-RCT) evaluates the effectiveness of a brief, single-session psychosocial workshop, "CETA Short Session" (CSS), for reducing symptoms of distress and functional impairment and increasing treatment engagement among conflict veterans and their families in Ukraine. The CSS workshop includes psychoeducation, review of a self-assessment, safety screening, and training in cognitive coping. This will be evaluated against a single-session comparison workshop that includes all of the same workshop elements except for cognitive coping. Registration for both conditions includes completion of a self-assessment. Participants with safety concerns or very severe symptoms will be immediately referred to mental health treatment; others will be asked to wait for one month before being reassessed and, if indicated, referred to mental health treatment. Both conditions include an individual check-in phone call one week after the workshop. Distress and functional impairment outcomes will be assessed one month from baseline. Treatment engagement outcomes will be assessed three months from referral. The investigators hypothesize that individuals attending sessions randomized to CSS will show greater improvement in mental health outcomes and greater treatment engagement than those attending sessions randomized to the comparison condition. With the onset of the COVID-19 pandemic in Spring 2019, the RCT was paused to develop and pilot an online version of both the CSS and comparison workshop. The trial protocol has now been expanded to continue the effectiveness trial while allowing for both online and [when/if feasible] in-person intervention delivery.
Description: International Depression Symptom Scale (IDSS): a locally-validated self-report instrument that produces total and syndrome-specific scores. (range: 0-54, higher indicates more symptomatic)
Measure: Change in mental health symptom scores Time: Baseline, 1-month follow-upDescription: Follow-up on referral to mental health treatment, derived from client monitoring records (indicated as yes/no)
Measure: Mental health treatment engagement Time: 3 months following referral to mental health treatmentDescription: a locally developed (based on qualitative data) and validated self-report instrument that produces a functional impairment score (range: 0-56, higher scores indicate greater functional impairment)
Measure: Change in functional impairment Time: Baseline, 1-month follow-upDescription: Items adapted (based on qualitative data) from the Conflict Tactics Scale - Revised (range: 0-18, higher scores indicate more aggression)
Measure: Aggression Time: Baseline, 1-month follow-upDescription: Items adapted (based on qualitative data) from the Social Connectedness Scale - Revised (range: 0-24, higher scores indicate greater disconnection)
Measure: Social Connectedness Time: Baseline, 1-month follow-upDescription: AUDIT-C scores (range: 0-12, higher scores indicate greater substance use)
Measure: Alcohol consumption Time: Baseline, 1-month follow-upDescription: JHU Implementation Measure for LMIC (JHUIM): A validated implementation questionnaire assessing adoption, acceptability, appropriateness, and feasibility of the intervention.
Measure: Implementation outcomes Time: 1-month follow-upAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports